Frontier Capital Management CO LLC Apellis Pharmaceuticals, Inc. Transaction History

Frontier Capital Management CO LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $18,540 - $29,078	-487 Reduced 0.62%	77,561 $2.98 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $4.32 Million - $5.66 Million	78,048 New	78,048 $4.59 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $818,290 - $3.09 Million	34,600 New	34,600 $1.32 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $5,953 - $9,264	133 Added 2.19%	6,193 $423,000
Q2 2022 Jul 20, 2022	SELL	$35.07 - $59.21 $332,779 - $561,843	-9,489 Reduced 61.03%	6,060 $274,000
Q1 2022 Apr 14, 2022	SELL	$35.46 - $54.12 $3.83 Million - $5.84 Million	-107,941 Reduced 87.41%	15,549 $790,000
Q4 2021 Jan 19, 2022	SELL	$30.74 - $49.16 $4.69 Million - $7.49 Million	-152,420 Reduced 55.24%	123,490 $5.84 Million
Q3 2021 Oct 19, 2021	BUY	$31.4 - $69.84 $3.09 Million - $6.87 Million	98,385 Added 55.42%	275,910 $9.09 Million
Q2 2021 Aug 09, 2021	BUY	$40.9 - $64.9 $7.26 Million - $11.5 Million	177,525 New	177,525 $11.2 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Frontier Capital Management CO LLC with notifications on news.